Allarity Therapeutics authorizes $5M share repurchase program through Feb 2026

Allarity Therapeutics, Inc.

Board authorized repurchase of up to $5M of common stock; program runs through Feb 28, 2026.
CEO Thomas Jensen cites confidence in stenoparib’s clinical potential and long-term vision.
Company says sufficient cash position maintains runway into 2026, unaffected by buyback.
Repurchases discretionary; may be made via open market or other methods under Rule 10b-18.
Allarity is a Phase 2 clinical-stage biotech developing dual PARP/Wnt inhibitor stenoparib.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.